Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DOXYCYCLINE

All products: not a benefit

Other products in the same Health Canada class (J01AA) — coverage varies; not interchangeable

  • Doxycycline hyclate (PMS-Doxycycline): general benefit, Not a benefit
  • Minocycline (Minocycline): general benefit, Not a benefit
  • Tetracycline (Tetracyn): general benefit, Not a benefit
  • Tigecycline (Tygacil): general benefit

Apo-Doxycycline MR · DIN 02512645 · 40mg · MR capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Doxycycline MR · DIN 02512645 Manufacturer: Apotex Inc.; listing date 2021-07-30 Health Canada: Marketed since 2021-09-01 · brand APO-DOXYCYCLINE MR · ATC J01AA02 DOXYCYCLINE · form Capsule (immediate- and delayed-release) · route Oral · ingredients DOXYCYCLINE (DOXYCYCLINE MONOHYDRATE) 40 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100192 · Verify on the e-Formulary ↗ (DIN 02512645)

Source record
DIN 02512645: Apo-Doxycycline MR Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 081224027; group id 31; item number 0065; lccId None; manufacturer id APX Source form: MR Cap; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $3.1871; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02512645 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100192
Interchangeable products
Apprilon · DIN 02375885 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:12:24 Tetracyclines) and how they are covered

Matched class: 08:12:24 Tetracyclines

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: TIGECYCLINE Some products covered without a code (check the product listing): DOXYCYCLINE HYCLATE, MINOCYCLINE HCL, TETRACYCLINE 08:12:24 Tetracyclines

DOXYCYCLINE HYCLATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (2), Listed, not a benefit (1), General benefit (7) · strengths: 20mg, 100mg · Cap, Tab

MINOCYCLINE HCL

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 50mg, 100mg · Cap

TETRACYCLINE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

TIGECYCLINE

· 1 products · General benefit · strengths: 50mg/Vial · Pd for Inj-5mLVial Pk (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:24
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE APPRILON® (doxycycline) modified-release capsule is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. No meaningful effect was demonstrated for generalized erythema (redness) of rosacea. APPRILON® contains an antibacterial ingredient, doxycycline. Misuse or overuse of APPRILON® could lead to the development of drug-resistant bacteria. To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline, APPRILON® should only be used for the authorized indication and clinical use. Pediatrics (<18 years of age): Safety and efficacy in children below the age of 18 years have not been established. Geriatrics (≥ 65 years of age): Clinical studies of APPRILON did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. https://pdf.hres.ca/dpd_pm/00045712.PDF PM date: May 31, 2018 Source product: APPRILON; DIN 02375885; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Apo-Doxycycline MR: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026